Name

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for T-2 protocol

Name

Alternate Names

Actinomycin
Actinomycin AIV
Actinomycin C1
Actinomycin D
Actinomycin I1
Actinomycin IV
Actinomycindioic D-acid dilactone
Cosmegen
Dactino-mycin D
Meractinomycin
Oncostatin K

Abbreviations

ACD
ACT
ACT-D
ACTD
Acto-D
AD
Dact

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

003053
3053

Primary Site

Ewing's sarcoma
rhabdomyosarcoma
testicular cancer
Wilm's tumor

Histology

None

Remarks

FDA approved use on Ewing's sarcoma, rhabdomyosarcoma, gestational trophoblastic neoplasms, testicular carcinoma, Wilm's tumor (antitumor antibiotic)

Coding

This drug should be coded

Name

Alternate Names

14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin

Abbreviations

ADM
ADR
ADRI

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

123127

Primary Site

Bladder
breast
liver
multiple myeloma
ovarian
pancreatic
prostate cancer

Histology

None

Remarks

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

Coding

This drug should be coded

Name

Alternate Names

496
5-Azacitidine
5-Azacytidine
Antibiotic U-18
Azacitidine
Azacytidine
Ladakamycin

Abbreviations

5-AC
5-AZA
5-AZAC
5-AZCR
AZA-CR
AZC

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

102816

Primary Site

Myelodysplastic syndromes

Histology

Myelomonocytic leukemia

Remarks

May 27, 2022 FDA approved Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.


Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.

Coding

This drug should be coded

Name

Alternate Names

Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719

Abbreviations

CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

026271
26271

Primary Site

Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor

Histology

None

Remarks

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

Coding

This drug should be coded

Name

Alternate Names

Compound 37231
Leurocristine Sulfate
Oncovin
Vincasar
Vincasar PFS
Vincristine Sulfate
Vincrystine
Vinkristin

Abbreviations

LCR
VCR
VNCR

Category

Chemotherapy

Subcategory

Plant alkyloid--antimetabolite

NSC Number

067574
67574

Primary Site

None

Histology

None

Remarks

Antineoplastic; vinca plant alkaloid; antimetabolite. FDA approved uses in ALL, Hodgkin's lymphoma, non-Hodgkin's lymphoma, neuroblastoma, rhabomyosarcoma, and Wilm's tumor.

Coding

This drug should be coded
Glossary